Search the Newsreel

Technical Reactions to IRTC Trends in Macro Strategies

This article provides a technical analysis of Irhythm Technologies Inc. (NASDAQ: IRTC), highlighting near-term weak sentiment that may lead to a resumption of long-term weakness. It identifies a significant risk-reward short setup and offers three distinct AI-generated trading strategies with specific entry, target, and …

Form PRE 14A Algorhythm Holdings Inc For: 17 July By Investing.com

This article from Investing.com reports the filing of Form PRE 14A by Algorhythm Holdings Inc. on July 17. The brief report indicates the company's filing without providing further details about the content of the form. The article also includes various market data and links …

Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Merck & Company (MRK) and Viking Therapeutics (VKTX)

This article highlights recent bullish analyst ratings for three healthcare companies: Irhythm Technologies (IRTC), Merck & Company (MRK), and Viking Therapeutics (VKTX). Analysts from BTIG, Scotiabank, and Canaccord Genuity reiterated Buy ratings, providing price targets and noting potential upsides based on current stock levels. …

Law firm probes Rhythm Pharmaceuticals officers for possible self-dealing harming shareholders

Kuehn Law, PLLC is investigating officers and directors of Rhythm Pharmaceuticals, Inc. for alleged breaches of fiduciary duties through potential self-dealing. This investigation could result in damages for shareholders and corporate governance reforms. Long-term shareholders are advised to contact the law firm for a …

Is Rhythm Pharmaceuticals Poised for a Breakthrough in Hypothalamic Obesity

Rhythm Pharmaceuticals' drug, setmelanotide, shows promising Phase 3 results for acquired hypothalamic obesity (HO), targeting a potential FDA approval by March 20, 2026. This condition represents a significant unmet medical need with a substantial global patient population. Analysts project significant revenue growth for Rhythm …

Needham Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Maintains Target Price $255

Needham has reiterated its Buy rating for iRhythm Technologies (IRTC.US) and maintained a target price of $255. This continuation of a positive outlook suggests the firm sees sustained value or growth potential in the company.

IRhythm Holdings to Report Second Quarter 2026 Financial Results on August 6, 2026

iRhythm Holdings, Inc. announced it will release its second-quarter 2026 financial results after market close on Thursday, August 6, 2026. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results, with a live and archived …

Truist Adjusts Price Target on iRhythm Technologies to $160 From $174, Maintains Buy Rating

Truist has lowered its price target for iRhythm Technologies (IRTC) to $160 from $174, while reiterating a Buy rating on the stock. iRhythm Technologies is a digital healthcare company specializing in ambulatory cardiac monitoring services. The company recently increased its earnings guidance for the …

Wells Fargo Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $155

Wells Fargo has reiterated its Buy rating for Rhythm Pharmaceuticals (RYTM.US) and maintained its price target at $155. This continued positive outlook suggests the firm sees sustained value and growth potential for the pharmaceutical company.

iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by iRhythm Technologies, Inc. (NASDAQ:IRTC). The law firm encourages shareholders who purchased iRhythm securities before January 11, 2022, and still hold them, to contact them to assist with the investigation. The …

iRhythm’s Q2 Results Call Will Be Live After Aug. 6 Close

Algorhythm says SemiCab gained new brands, $9.5M cash infusion

Does iRhythm (IRTC) Balancing a Revenue Beat With In-Line Guidance Recast Its AI Cardiac Story?

Rhythm Pharmaceuticals Stock On Fire: Up 28% With 12-Day Winning Streak

Algorhythm Holdings, Inc. Actuals & Estimates (NASDAQ:RIME)

RYTM Forecast — Price Target — Prediction for 2027

8-Day Rally Sends Rhythm Pharmaceuticals Stock Up 24%

Algorhythm Holdings, Inc. (RIME) Upgraded to Buy: Here's What You Should Know

Rhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial Engine

Algorhythm Holdings, Inc. Q1 2026 Earnings Call Summary

Algorhythm Holdings, Inc. 1Q 2026: Revenue $2.4M, EPS $(0.52) — 10-Q Summary

Algorhythm Holdings Announces Record First Quarter 2026 Financial Results

Earnings call transcript: Algorhythm Holdings Q1 2026 sees strong revenue growth

AI logistics firm Algorhythm cuts losses as cash nears $11M

Rhythm (RYTM) Q1 2026 Earnings Call Transcript

Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday

Rhythm Pharmaceuticals Q1 Earnings Call Highlights

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates

IRTC Stock Up on Q1 Earnings & Revenue Beat, FY26 Outlook Raised

iRhythm (IRTC) Q1 2026 Earnings Transcript

iRhythm (IRTC) Reports Q1: Everything You Need To Know Ahead Of Earnings

Algorhythm Holdings Announces $12 Million Annualized Revenue Run Rate

Algorhythm Holdings, Inc. Reports Over 20% Revenue Growth, Surpassing $12 Million Annual Run Rate for SemiCab

iRhythm (IRTC): Buy, Sell, or Hold Post Q4 Earnings?

Algorhythm Holdings 2025 10-K: Revenue $4.39M; Net loss $(15.21M), $(5.86) EPS